Cargando…
Current advances related to Clostridium difficile infection
Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics suc...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418153/ https://www.ncbi.nlm.nih.gov/pubmed/25900952 |
_version_ | 1782369444247371776 |
---|---|
author | Kim, Yong Gil Jang, Byung Ik |
author_facet | Kim, Yong Gil Jang, Byung Ik |
author_sort | Kim, Yong Gil |
collection | PubMed |
description | Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics such as metronidazole and vancomycin are the treatment of choice for initial and first relapsing CDI. Active immunization with C. difficile toxins and faecal microbiota transplantation deserve special attention. Here we describe these strategies for difficult-to-treat CDI. |
format | Online Article Text |
id | pubmed-4418153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44181532015-05-12 Current advances related to Clostridium difficile infection Kim, Yong Gil Jang, Byung Ik Indian J Med Res Review Article Clostridium difficile infection (CDI) can trigger various responses, ranging from asymptomatic carriage to fulminant colitis. Hard-to-cure CDI, such as severe CDI, multiple recurrences of CDI, refractory CDI, and hypervirulent strains of C. difficile, require new treatments, although antibiotics such as metronidazole and vancomycin are the treatment of choice for initial and first relapsing CDI. Active immunization with C. difficile toxins and faecal microbiota transplantation deserve special attention. Here we describe these strategies for difficult-to-treat CDI. Medknow Publications & Media Pvt Ltd 2015-02 /pmc/articles/PMC4418153/ /pubmed/25900952 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kim, Yong Gil Jang, Byung Ik Current advances related to Clostridium difficile infection |
title | Current advances related to Clostridium difficile infection |
title_full | Current advances related to Clostridium difficile infection |
title_fullStr | Current advances related to Clostridium difficile infection |
title_full_unstemmed | Current advances related to Clostridium difficile infection |
title_short | Current advances related to Clostridium difficile infection |
title_sort | current advances related to clostridium difficile infection |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418153/ https://www.ncbi.nlm.nih.gov/pubmed/25900952 |
work_keys_str_mv | AT kimyonggil currentadvancesrelatedtoclostridiumdifficileinfection AT jangbyungik currentadvancesrelatedtoclostridiumdifficileinfection |